Standard BioTools Inc (NASDAQ: LAB) is 1.36% higher on its value in year-to-date trading and has touched a low of $1.57 and a high of $3.16 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The LAB stock was last observed hovering at around $2.32 in the last trading session, with the day’s loss setting it -0.08%.
Currently trading at $2.24, the stock is 6.69% and 1.80% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.6 million and changing -3.45% at the moment leaves the stock -3.16% off its SMA200. LAB registered -8.57% loss for a year compared to 6-month loss of -2.61%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 29.48% gain in the last 1 month and extending the period to 3 months gives it a -9.68%, and is -0.44% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.54% over the week and 6.26% over the month.
Standard BioTools Inc (LAB) has around 539 employees, a market worth around $829.74M and $126.76M in sales. Profit margin for the company is -107.28%. Distance from 52-week low is 42.68% and -29.11% from its 52-week high. The company has generated returns on investments over the last 12 months (-22.34%).
The EPS is expected to grow by 62.06% this year
The shares outstanding are 370.42M, and float is at 360.62M with Short Float at 5.39%.
Standard BioTools Inc (LAB) Insider Activity
The most recent transaction is an insider purchase by Casdin Partners Master Fund, L, the company’s Director. SEC filings show that Casdin Partners Master Fund, L bought 100,000 shares of the company’s common stock on May 23 ’24 at a price of $2.60 per share for a total of $0.26 million. Following the purchase, the insider now owns 46.08 million shares.
Standard BioTools Inc disclosed in a document filed with the SEC on May 22 ’24 that Casdin Partners Master Fund, L (Director) bought a total of 150,000 shares of the company’s common stock. The trade occurred on May 22 ’24 and was made at $2.58 per share for $0.39 million. Following the transaction, the insider now directly holds 45.98 million shares of the LAB stock.
Still, SEC filings show that on May 21 ’24, Casdin Partners Master Fund, L (Director) acquired 350,000 shares at an average price of $2.56 for $0.9 million. The insider now directly holds 45,825,821 shares of Standard BioTools Inc (LAB).
